公开(公告)号：US20240358840A1

公开(公告)日：2024-10-31

申请号：US18762112

申请日：2024-07-02

申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED

发明人： Sidney L. WEISS

IPC分类号： A61K47/44 ,  A61K9/00 ,  A61K9/107 ,  A61K31/425 ,  A61K47/10

CPC分类号： A61K47/44 ,  A61K9/0048 ,  A61K9/1075 ,  A61K31/425 ,  A61K47/10

摘要： Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

公开(公告)号：US12128134B2

公开(公告)日：2024-10-29

申请号：US17987989

申请日：2022-11-16

申请人： Ruminant Biotech Corp Limited

发明人： Mark Christopher Lay ,  Hayden Peter Thomas ,  Neil Richard Gladden ,  David Leslie Hayman ,  Geoffrey Earle Corbett ,  Prabhat Bhusal

IPC分类号： A61K33/00 ,  A61K9/00 ,  A61K47/34 ,  A61K47/44

CPC分类号： A61K9/0068 ,  A61K33/00 ,  A61K47/34 ,  A61K47/44

摘要： The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein the dosage form and the bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

公开(公告)号：US20240350590A1

公开(公告)日：2024-10-24

申请号：US18577592

申请日：2022-07-08

申请人： HANMI PHARM. CO., LTD.

发明人： Go-Wun CHOI ,  Hyuk-Jun CHO ,  Ho-Taek IM ,  Yong-ll KIM

IPC分类号： A61K38/22 ,  A61K9/00 ,  A61K47/44

CPC分类号： A61K38/2278 ,  A61K9/0053 ,  A61K47/44

摘要： A composition, suitable for an orally administered formulation, contains a GLP-1 analogue and, particularly, a hydrophobic ion-pair of a GLP-1 analogue and an oil phase. The pharmaceutical composition for oral administration forms an emulsion surrounding the hydrophobic ion-pair when exposed to a water phase, so as to be stably absorbed without being decomposed by digestive enzymes, and thus provides an effective and prolonged pharmacological effect. Methods for producing the composition for oral administration are also disclosed.

公开(公告)号：US20240350439A1

公开(公告)日：2024-10-24

申请号：US18759093

申请日：2024-06-28

申请人： METIMEDI PHARMACEUTICALS CO., LTD.

发明人： Chong Hwan CHANG ,  Keun-Yeong JEONG

IPC分类号： A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00

CPC分类号： A61K31/19 ,  A23L33/10 ,  A23L33/165 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/5026 ,  A61K9/5042 ,  A61K33/06 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40 ,  A61K47/44 ,  A61P35/00 ,  A23V2002/00 ,  A23V2200/308 ,  A23V2250/042 ,  A23V2250/1578

摘要： The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

公开(公告)号：US20240350409A1

公开(公告)日：2024-10-24

申请号：US18142619

申请日：2023-05-03

申请人： LifeActive, Inc.

发明人： Calvin Dexter Morris

IPC分类号： A61K9/107 ,  A61K9/00 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K9/1075 ,  A61K9/0014 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44

摘要： Provided are transdermal delivery formulations, and methods for the manufacture thereof, for the epicutaneous administration of drugs and nutrients to a human subject or domestic, veterinary, or agricultural animal. Transdermal delivery formulations disclosed herein comprise a homogenous mixture of (a) a transdermal accelerant comprising a weak organic acid having a pKa greater than 2.0 and (b) a microemulsion comprising a nonionic emulsifier, water, and a cis-unsaturated long-chain fatty acid. Fatty acid microemulsions are combined with the acidified transdermal accelerants having a pH greater than 1.0 (typically from 1.5 to 2.5) to yield a homogenous transdermal delivery formulation comprising fatty acid micelles and/or liposomes that encapsulate one or more compound, such as a nutrient or a drug, and incorporate one or more cis-unsaturated fatty acid having a 12-26 carbon chain that includes one or more double bond in a cis configuration.

公开(公告)号：US20240350401A1

公开(公告)日：2024-10-24

申请号：US18756671

申请日：2024-06-27

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ,  LYOTROPIC DELIVERY SYSTEMS LTD

发明人： Nissim GARTI ,  Sharon GARTI LEVI

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/136 ,  A61K31/723 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K31/136 ,  A61K31/723 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

摘要： The disclosure concerns viscous or gelled delivery systems based on oily nano-domains dispersed in a viscosified/gelled continuous aqueous phase, and suitable for prolonged and/or sustained topical delivery of various active compounds.

公开(公告)号：US20240335381A1

公开(公告)日：2024-10-10

申请号：US18629522

申请日：2024-04-08

申请人： Quicksilver Scientific, Inc.

发明人： Christopher W. Shade ,  Steven Tieu ,  James R Huey

IPC分类号： A61K9/107 ,  A61K9/00 ,  A61K31/57 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61P5/24

CPC分类号： A61K9/1075 ,  A61K9/0014 ,  A61K31/57 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61P5/24

摘要： Thickened microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described thickened microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the thickened MOIW microemulsion are modified with alcohol and an alcohol-lipid phase thickener and can solubilize alcohol-soluble species, including nonderivatized hormones. Preferably, the modified oil phase droplets of the thickened MOIW microemulsion directly solubilize nonderivatized hormones. The polar continuous “water” phase of the thickened MOIW microemulsion is modified with a continuous phase thickener. The modified oil phase droplets disperse into the modified polar continuous phase of the thickened MOIW microemulsion.

公开(公告)号：US20240325295A1

公开(公告)日：2024-10-03

申请号：US18578751

申请日：2022-04-12

申请人： DriPel B.V.

发明人： Hubert Clemens Pellikaan ,  Vincent Jean Hendrik Michel Van Driel

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K31/196 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61M15/00 ,  A61M15/08

CPC分类号： A61K9/0043 ,  A61K9/08 ,  A61K31/196 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61M15/0065 ,  A61M15/08 ,  A61M2202/0468

摘要： Provided herein is an aqueous bumetanide-containing liquid that can suitably be used for transmucosal administration of bumetanide. The aqueous liquid includes 0.3-5 wt. % bumetanide, 2-30 wt. % of a non-ionic surfactant having an HLB of more than 10, and 65-94 wt. % water, in which the liquid has a pH at 25° C. in the range of 5-9 and each of the bumetanide and the non-ionic surfactant is dissolved and/or contained in colloidal particles having a diameter of less than 50 nm. The aqueous liquid offers the advantage that it can accommodate relatively high concentrations of bumetanide. Excellent bioavailability can be achieved upon transmucosal administration of the aqueous bumetanide-containing liquid. The aqueous liquid further offers the highly desirable advantage that it does not cause irritation, e.g. stinging or itching, when administered in this manner.

公开(公告)号：US12102710B2

公开(公告)日：2024-10-01

申请号：US17353956

申请日：2021-06-22

申请人： CROWN LABORATORIES, INC.

发明人： Thomas M. Hitchcock ,  Sasima Phadungpojna ,  Matthew D. Stephens ,  Mun Su Rhee

IPC分类号： A61K8/99 ,  A61K8/02 ,  A61K8/04 ,  A61K8/19 ,  A61K8/34 ,  A61K8/37 ,  A61K8/67 ,  A61K8/73 ,  A61K8/88 ,  A61K8/92 ,  A61K8/9789 ,  A61K9/06 ,  A61K9/19 ,  A61K31/07 ,  A61K35/741 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46 ,  A61Q19/00

CPC分类号： A61K8/99 ,  A61K8/022 ,  A61K8/042 ,  A61K8/19 ,  A61K8/34 ,  A61K8/37 ,  A61K8/671 ,  A61K8/735 ,  A61K8/88 ,  A61K8/922 ,  A61K8/9789 ,  A61K9/06 ,  A61K9/19 ,  A61K31/07 ,  A61K35/741 ,  A61K47/14 ,  A61K47/34 ,  A61K47/44 ,  A61K47/46 ,  A61Q19/00 ,  A61K2800/524 ,  A61K2800/594

摘要： Described herein are dermatological compositions, formulations containing wild type or genetically modified Cutibacterium bacteria and methods for use thereof of skin. The cosmetic and therapeutic formulations described herein can be used as cosmetic daily skin treatments or for treating skin inflammation or disorders including acne, psoriasis, rosacea, dermatitis, or eczema.

公开(公告)号：US20240316077A1

公开(公告)日：2024-09-26

申请号：US18612067

申请日：2024-03-21

申请人： Fertin Pharma A/S

发明人： Sanne Skov Jensen ,  Gitte Nykjær Nikolajsen ,  Simon Laursen ,  Dorthe Schackinger Boesen

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

CPC分类号： A61K31/658 ,  A61K9/0056 ,  A61K36/3482 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

摘要： An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.